110 related articles for article (PubMed ID: 9215822)
21. A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen.
Morrissey JJ; Raney S
Cell Biol Int; 1998; 22(6):413-9. PubMed ID: 10328849
[TBL] [Abstract][Full Text] [Related]
22. Breast cancer axillary lymph node metastasis detection by a high-resolution dedicated breast camera: a comparative study with SPECT and pinhole SPECT.
Spanu A; Chessa F; Sanna D; Cottu P; Manca A; Nuvoli S; Madeddu G
Cancer Biother Radiopharm; 2007 Dec; 22(6):799-811. PubMed ID: 18158771
[TBL] [Abstract][Full Text] [Related]
23. Estrogen receptor imaging with 17 alpha-[123I]iodovinyl-11 beta-methoxyestradiol (MIVE2)--Part II. Preliminary results in patients with breast carcinoma.
Ribeiro-Barras MJ; Foulon C; Baulieu JL; Guilloteau D; Bougnoux P; Lansac J; Besnard JC
Int J Rad Appl Instrum B; 1992 Apr; 19(3):263-7. PubMed ID: 1629015
[TBL] [Abstract][Full Text] [Related]
24. Radioimaging of human breast carcinoma xenografts in mice by [123I]-labeled Z-17 alpha-iodovinyl-11 beta-chloromethyl-estradiol.
Zeicher M; Delcorde A; Quivy J; Dupuis Y; Vervist A; Frühling J
Nucl Med Biol; 1996 Jan; 23(1):69-73. PubMed ID: 9004917
[TBL] [Abstract][Full Text] [Related]
25. Comparison of 99mtechnetium-pertechnetate and 123iodide SPECT with FDG-PET in patients suspicious for breast cancer.
Buchmann I; Riedmüller K; Hoffner S; Mack U; Aulmann S; Haberkorn U
Cancer Biother Radiopharm; 2007 Dec; 22(6):779-89. PubMed ID: 18158769
[TBL] [Abstract][Full Text] [Related]
26. 18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis.
Osborne JR; Port E; Gonen M; Doane A; Yeung H; Gerald W; Cook JB; Larson S
J Nucl Med; 2010 Apr; 51(4):543-50. PubMed ID: 20237034
[TBL] [Abstract][Full Text] [Related]
27. Measuring residual estrogen receptor availability during fulvestrant therapy in patients with metastatic breast cancer.
van Kruchten M; de Vries EG; Glaudemans AW; van Lanschot MC; van Faassen M; Kema IP; Brown M; Schröder CP; de Vries EF; Hospers GA
Cancer Discov; 2015 Jan; 5(1):72-81. PubMed ID: 25380844
[TBL] [Abstract][Full Text] [Related]
28. Estrogen receptor scintigraphy.
Scheidhauer K; Scharl A; Schicha H
Q J Nucl Med; 1998 Mar; 42(1):26-32. PubMed ID: 9646642
[TBL] [Abstract][Full Text] [Related]
29. Imaging, biodistribution and therapy potential of halogenated tamoxifen analogues.
Yang DJ; Li C; Kuang LR; Price JE; Buzdar AU; Tansey W; Cherif A; Gretzer M; Kim EE; Wallace S
Life Sci; 1994; 55(1):53-67. PubMed ID: 8015349
[TBL] [Abstract][Full Text] [Related]
30. Radioiodinated estradiol dimer for estrogen receptor targeted breast cancer imaging.
Xu D; Peng C; Gao F; Guo Z; Zhuang R; Su X; Zhang X
Chem Biol Drug Des; 2020 Dec; 96(6):1332-1340. PubMed ID: 32603003
[TBL] [Abstract][Full Text] [Related]
31. Breast cancer: PET imaging of estrogen receptors.
Mintun MA; Welch MJ; Siegel BA; Mathias CJ; Brodack JW; McGuire AH; Katzenellenbogen JA
Radiology; 1988 Oct; 169(1):45-8. PubMed ID: 3262228
[TBL] [Abstract][Full Text] [Related]
32. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays.
Dehdashti F; Mortimer JE; Siegel BA; Griffeth LK; Bonasera TJ; Fusselman MJ; Detert DD; Cutler PD; Katzenellenbogen JA; Welch MJ
J Nucl Med; 1995 Oct; 36(10):1766-74. PubMed ID: 7562040
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and biological properties of 7alpha-cyano derivatives of the (17alpha,20E/Z)-[125I]iodovinyl- and 16alpha-[125I]iodo-estradiols.
Ali H; Rousseau J; Paquette B; Dubé C; Marko B; van Lier JE
Steroids; 2003 Dec; 68(14):1189-200. PubMed ID: 14643881
[TBL] [Abstract][Full Text] [Related]
34. Clinical production, stability studies and PET imaging with 16-alpha-[18F]fluoroestradiol ([18F]FES) in ER positive breast cancer patients.
Kumar P; Mercer J; Doerkson C; Tonkin K; McEwan AJ
J Pharm Pharm Sci; 2007; 10(2):256s-265s. PubMed ID: 17718929
[TBL] [Abstract][Full Text] [Related]
35. Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials.
Alberts SR; Ingle JN; Roche PR; Cha SS; Wold LE; Farr GH; Krook JE; Wieand HS
Cancer; 1996 Aug; 78(4):764-72. PubMed ID: 8756370
[TBL] [Abstract][Full Text] [Related]
36. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
37. 131I SPECT/CT in the follow-up of differentiated thyroid carcinoma: incremental value versus planar imaging.
Spanu A; Solinas ME; Chessa F; Sanna D; Nuvoli S; Madeddu G
J Nucl Med; 2009 Feb; 50(2):184-90. PubMed ID: 19164225
[TBL] [Abstract][Full Text] [Related]
38. Technetium-99m-MIBI scintimammography by planar and SPECT imaging in the diagnosis of breast carcinoma and axillary lymph node involvement.
Myslivecek M; Koranda P; Kamínek M; Husák V; Hartlová M; Dusková M; Cwiertka K
Nucl Med Rev Cent East Eur; 2004; 7(2):151-5. PubMed ID: 15968602
[TBL] [Abstract][Full Text] [Related]
39. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer.
Mortimer JE; Dehdashti F; Siegel BA; Trinkaus K; Katzenellenbogen JA; Welch MJ
J Clin Oncol; 2001 Jun; 19(11):2797-803. PubMed ID: 11387350
[TBL] [Abstract][Full Text] [Related]
40. Incremental value of 131I SPECT/CT in the management of patients with differentiated thyroid carcinoma.
Chen L; Luo Q; Shen Y; Yu Y; Yuan Z; Lu H; Zhu R
J Nucl Med; 2008 Dec; 49(12):1952-7. PubMed ID: 18997044
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
